NCT Number: NCT05498272
Phase: Phase 2
Trial Summary: Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Rana McKay, MD
Acronym: NePtune
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives